Skip to main content

Table 1 Socio-demographic and clinical characteristics of patients included in the study

From: Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study

Patient characteristics

Minimal (n = 43)

Type 1 (n = 12)

Type 2 (n = 31)

Mixed (n = 34)

p value

Socio-demographics, N (%)

     

 Black

24 (56%)

11 (92%)

14 (45%)

19 (56%)

0.04

 Female

42 (98%)

11 (92%)

31 (100%)

30 (88%)

0.08

 Medically disabled

10 (23%)

4 (33%)

14 (45%)

19 (56%)

0.03

 Employed

23 (53%)

6 (55%)

13 (43%)

13 (35%)

0.4

 Medicaid insurance

3 (7%)

4 (33%)

7 (23%)

7 (21%)

0.07

 Married

23 (53%)

3 (25%)

14 (45%)

14 (41%)

0.3

 ≥ College education

27 (63%)

5 (45%)

16 (52%)

16 (47%)

0.5

Clinical factors, median (IQR)

     

 Age

44 (34–52)

35 (29–46)

46 (35–57)

41 (33–50)

0.3

 Years since diagnosis

15 (7–22)

16 (12–28)

15 (8–21)

14 (9–20)

0.6

Measures of Type 1 SLE activity, median (IQR)

     

 SLEDAI

0 (0–2)

7 (5–10)

0 (0–2)

6 (4–8)

< 0.0001

 Clinical SLEDAI

0 (0–0)

3 (0–4)

0 (0–0)

4 (2–6)

< 0.0001

 Type 1 PGA

0 (0–0.2)

1 (0.5–1.5)

0 (0–0.5)

1 (0.5–1.5)

< 0.0001

 Active nephritis

0 (0%)

5 (42%)

0 (0%)

8 (23%)

< 0.0001

Measures of Type 2 SLE activity, median (IQR)

     

 PSD score

4 (1–5)

5 (2–6)

10 (8–14)

11 (8–18)

< 0.0001

 Type 2 PGA

0 (0–0.2)

0 (0–0.5)

1 (0.5–2)

1 (1–2)

< 0.0001

 Fulfilled FM criteria

0%

0%

13%

35%

< 0.0001

  1. IQR interquartile range, PGA physician global assessment, range 0–3, PSD polysymptomatic distress, range 0–31, SLEDAI systemic lupus erythematosus disease activity index, range 0–105, FM fibromyalgia, according to the 2016 ACR Criteria [31]